PA
BEAM icon

Perceptive Advisors’s Beam Therapeutics BEAM Stock Holding History

Perceptive Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-537,635
Closed -$46.8M – 150
2021
Q3 		$46.8M Hold
537,635
– – 0.68% 36
2021
Q2 		$69.2M Hold
537,635
– – 0.9% 31
2021
Q1 		$37.8M Buy
+537,635
New +$51.1M 0.48% 52

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Perceptive Advisors's BEAM Position: Q4 2021 in Review

Perceptive Advisors sold out of Beam Therapeutics (BEAM) in Q4 2021, closing a stake of 537,635 shares — an estimated $46.8M sold.

Perceptive Advisors first reported a position in BEAM in Q1 2021 and held it in 3 quarters. The position peaked at $69.2M in Q2 2021. 232 funds tracked by Wall St. Rank hold BEAM as of Q4 2021.

  • Perceptive Advisors reported no remaining Beam Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Perceptive Advisors sold 537,635 Beam Therapeutics shares in Q4 2021, an estimated $46.8M.
  • Perceptive Advisors first reported a position in Beam Therapeutics in Q1 2021 and held it in 3 quarters.
  • Perceptive Advisors's Beam Therapeutics position peaked at $69.2M in Q2 2021.
  • 232 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2021.

Based on Perceptive Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.